Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Fresh Market's 16th Annual Sidewalk Sale to benefit Juvenile Diabetes Research Foundation

The Fresh Market will hold its 16th annual "Hope Floats" Sidewalk Sale on September 10 through September 12, from 11:00 a.m. to 6:00 p.m. daily to benefit the Juvenile Diabetes Research Foundation (JDRF). The Fresh Market's stores, located in 20 states across the Southeast, Midwest, Mid-Atlantic and Northeast, will offer root beer floats, hot dogs, gourmet cookies and ice cream sundaes in exchange for a donation to JDRF in support of its mission to find a cure for diabetes and its complications.

3 Sep 2010

Special empowerment program to promote confidence in diabetic children

Teens are learning how to shred down the mountain and balance blood sugars in a special empowerment program called Riding on Insulin, taking place December 11, 2010, at The Canyons Resort in Park City. The day, led by Sean Busby,26 year old professional snowboarder with type 1 diabetes promotes courage and confidence and shows children with type 1 or type 2 they can overcome mental and physical challenges.

24 Aug 2010

Discovery on stem cell can create new opportunity in organ regeneration field

Taking one type of cell and transforming it into another type is now possible. Cells taken from the thymus have been transformed into skin cells,a discovery that may have important ramifications for the field of organ regeneration.

19 Aug 2010

JDRF announces key step on road to artificial pancreas

JDRF announced today another important step on the road to the development of an artificial pancreas - an automated system to better manage the blood sugar of people with type 1 diabetes - with the establishment of a research program to speed the development of faster-acting insulin.

17 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

New implantable sensor to continuously monitor tissue glucose

Bioengineers at the University of California, San Diego and GlySens Incorporated have developed an implantable glucose sensor and wireless telemetry system that continuously monitors tissue glucose and transmits the information to an external receiver. The paper, published in the July 28, 2010 issue of the journal Science Translational Medicine, describes the use of this glucose-sensing device as an implant in animals for over one year. After human clinical trials and FDA approval, the device may be useful to people with diabetes as an alternative to finger sticking and short-term, needle-like glucose sensors that have to be replaced every three to seven days.

29 Jul 2010

Human insulin-producing beta cell replication sustained with single stimulatory molecule: Study

With a single stimulatory molecule, human insulin-producing beta cell replication can be sustained for at least four weeks in a mouse model of diabetes, according to researchers at the University of Pittsburgh School of Medicine in Diabetes, a journal of the American Diabetes Association.

28 Jul 2010

Osteocalcin hormone can regulate glucose levels: Research

Researchers led by Columbia University Medical Center have discovered that the skeleton plays an important role in regulating blood sugar and have further illuminated how bone controls this process. The finding, published in Cell, is important because it may lead to more targeted drugs for type 2 diabetes.

23 Jul 2010

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer-cancer stem cells (CSCs).The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.

17 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

Study: Disruption of genes that control circadian rhythms may lead to diabetes

Disruption of two genes that control circadian rhythms can lead to diabetes, a researcher at UT Southwestern Medical Center has found in an animal study. Mice with defective copies of the genes, called CLOCK and BMAL1, develop abnormalities in pancreatic cells that eventually render the cells unable to release sufficient amounts of insulin.

14 Jul 2010

Free Test B4U Drive program for teens with diabetes

Medtronic, Inc. announced today that Test B4U Drive, the first-ever, free program for teens with diabetes combining advanced driver skills training with diabetes management education, will be held July 19-21 at The Forum in Los Angeles. In partnership with the Juvenile Diabetes No Limits Foundation, Medtronic will continue the program throughout the summer across the country to teach teens with diabetes that good diabetes management is a key to staying safe behind the wheel.

13 Jul 2010

Stanford University, OHSU receive grants to study VIAject for treating patients with diabetes

Biodel Inc. announced today the award of two research grants by the Juvenile Diabetes Research Foundation to Stanford University and Oregon Health & Science University to evaluate the use of VIAject (ultra-rapid-acting injectable human insulin) in the treatment of diabetes.

12 Jul 2010

Abbott’s plans to aid diabetes research if elected

Opposition Leader Tony Abbott announced last Saturday that he would be rolling out a $35 million funding for a clinical trial network (CTN) to improve the health of Australians with diabetes if he is elected as Prime Minister. The Rudd Governments $5million to the CTN will be supplemented by these funds. “This is one Coalition commitment I would be very happy for the government to match,” he said.

4 Jul 2010

Transplanted beta cells protect themselves by adapting to their new homes

For transplanted beta cells, life is tough. Not only are the insulin-producing cells in a stranger's body, tucked into the liver rather than the pancreas, they are a bit short on oxygen and blood, and they are often exposed to raised levels of glucose.

3 Jul 2010

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

Researchers funded by JDRF have discovered that the hormone, serotonin, may be involved in the increase of insulin-producing beta cells during pregnancy.

29 Jun 2010

Artificial pancreas holds promise for treating Type 1 diabetes

Shawna Wood would like nothing better than to go back to bed for another 24 hours of perfect blood sugar control. The 50-year old Wilsonville, Ore. woman has Type 1 diabetes, and she recently took part in a clinical trial of an automated replacement for her pancreas, which stopped producing insulin 9 years ago.

29 Jun 2010

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.

28 Jun 2010

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

28 Jun 2010

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Fresh Market's 16th Annual Sidewalk Sale to benefit Juvenile Diabetes Research Foundation

Special empowerment program to promote confidence in diabetic children

Discovery on stem cell can create new opportunity in organ regeneration field

JDRF announces key step on road to artificial pancreas

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

New implantable sensor to continuously monitor tissue glucose

Human insulin-producing beta cell replication sustained with single stimulatory molecule: Study

Osteocalcin hormone can regulate glucose levels: Research

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

Evotec to acquire DeveloGen

Study: Disruption of genes that control circadian rhythms may lead to diabetes

Free Test B4U Drive program for teens with diabetes

Stanford University, OHSU receive grants to study VIAject for treating patients with diabetes

Abbott’s plans to aid diabetes research if elected

Transplanted beta cells protect themselves by adapting to their new homes

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

Artificial pancreas holds promise for treating Type 1 diabetes

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Industry Focus eBook - Medical device (1st edition) eBook

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Industry Focus eBook - Medical device (1st edition) eBook

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Newsletters you may be interested in